Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY21 results · Apr–Jun 2020
Suven Life Sciences reported revenue from operations of ₹1.43 crore (down 99.3% from Q1 FY20) and net loss of ₹10.49 crore for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.43 | 198.99 | −99.3% | 8.66 | −83.5% |
| Other income | 2.53 | 3.01 | −15.9% | 3.00 | −15.6% |
| Total income | 3.96 | 201.99 | −98.0% | 11.66 | −66.0% |
| Profit before tax | (12.96) | 55.21 | Turned loss | (23.36) | Loss narrowed |
| Net profit for the period | (10.49) | 26.21 | Turned loss | (25.56) | Loss narrowed |
| EPS, basic (₹) | (0.82) | 2.06 | Turned loss | (2.01) | Loss narrowed |
| Net margin (%) | -734.2 | 13.2 | -295.1 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.43 | 198.99 | −99.3% | 8.66 | −83.5% |
| Other income | 2.53 | 3.01 | −15.9% | 3.00 | −15.6% |
| Total income | 3.96 | 201.99 | −98.0% | 11.66 | −66.0% |
| Profit before tax | (6.54) | 86.18 | Turned loss | (0.36) | Loss widened |
| Net profit for the period | (4.08) | 57.18 | Turned loss | (2.56) | Loss widened |
| EPS, basic (₹) | (0.32) | 4.49 | Turned loss | (0.20) | Loss widened |
| Net margin (%) | -285.4 | 28.7 | -29.6 |
Consolidated
- Filed with BSE
- 12 Aug 2020, 15:09 IST
- Board meeting
- 11 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2020, 15:09 IST
- Board meeting
- 11 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE